Covidien, a medical device manufacturer based in Mansfield, Massachusetts, announced that it ended the enrollment period for clinical studies of its Durability and Visibility iliac stents. According to a press release by the company, the multinational clinical studies are designed to test the safety and efficacy of self-expanding stents against balloon stents for the treatment of peripheral artery disease in iliac arteries.

In the study, 50 percent of participants will receive the PAD treatment with a balloon stent. The other half of participants will be treated with the self-expanding stents. The clinical study will take place at 23 different medical centers in Europe and the United States. All patients in the study will undergo a 9 month evaluation with 36 months of follow-up.

Dr. Mark Turco is Chief Medical Officer at Covidien. In prepared remarks, he said, "We are very pleased to report the completion of enrollment in these 2 studies, as the results will add important clinical data around treatment of patients with PAD.”

References

http://investor.covidien.com/phoenix.zhtml?c=207592&p=irol-news&nyo=0